Vanda Pharmaceuticals INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Vanda Pharmaceuticals reported a significantly wider net loss in 2025, driven by increased R&D and commercialization expenses, despite new product approvals and growth in Fanapt sales.
NASDAQ
Vanda Pharmaceuticals' 2024 10-K filing reveals a year of strategic shifts, including a new acquisition and ongoing patent battles, impacting its financial performance and future outlook.
NASDAQ
10-K: Vanda Pharmaceuticals Inks Deal to Acquire PONVORY Rights, Faces Generic Competition for HETLIOZ
Vanda Pharmaceuticals acquires PONVORY rights for $100 million while navigating generic competition for HETLIOZ and pursuing regulatory approvals for other pipeline products.